Clinical trials: Pregnancy
Chronic Kidney Disease
everlinQ endoAVF Post Market Study
Prospective, multi-center study to evaluate the everlinQ endoAVF System when used to create an endovascular arteriovenous fistula (endoAVF) for patients who require vascular access for hemodialysis.
- Trial name
- NCT02682420
- Testing
- everlinQ endoAVF System
- Where
- 11 sites in Canada, Germany and 1 more
- Volunteers
- 100 people
- Sponsor
- C. R. Bard
Female Infertility
Recombinant Follicle-stimulating Hormone in Treatment for Infertility
This is a randomized multi-centre, assessor-blind, parallel-group study to be conducted in 250 women in the age group of 20 to 39 years (both inclusive), who are indicated to undergo COS as part of assisted reproductive…
- Trial name
- REFRESH (NCT05266924)
- Testing
- Recombinant Human Follicle Stimulating Hormone 900 IU (66.0 μg) / 1.5mL Solution for Injection in Prefilled Pen
- Where
- India
- Volunteers
- 250 people
- Sponsor
- Bharat Serums and Vaccines Limited
Secondary Hyperparathyroidism, End Stage Renal Disease
Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis
The purpose of this study is to see if Zemplar, a vitamin D medication, safely and effectively decreases parathyroid hormone in children ages 2-20 with End Stage Renal Disease.
- Trial name
- NCT00053547
- Testing
- paricalcitol injection
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Abbott
Peritoneal Dialysis, Chronic Kidney Disease
Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis
The purpose of this study is to demonstrate that sevelamer hydrochloride is non-inferior to calcium acetate for the treatment of hyperphosphataemia in patients receiving peritoneal dialysis.
- Trial name
- NCT00196755
- Testing
- Sevelamer Hydrochloride (Renagel®), Calcium acetate (PhosLo® )
- Where
- 17 sites in Belgium, Denmark and 5 more
- Volunteers
- 138 people
- Sponsor
- Genzyme, a Sanofi Company
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Bacterial Vaginosis
DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)
This is a multicenter, randomized, double-blind, placebo-controlled study of DARE-BV1 (clindamycin phosphate vaginal gel, 2%) (QD x 1 day) compared to placebo vaginal gel (HEC Universal Placebo Gel) (QD × 1 day) for the treatment…
- Trial name
- NCT04370548
- Testing
- DARE-BV1clindamycin phosphate vaginal gel, 2%
- Where
- 10 sites in United States
- Volunteers
- 307 people
- Sponsor
- Daré Bioscience, Inc.
Advanced Solid Tumors
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment
Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment.
- Trial name
- NCT02301117
- Testing
- TAS-102
- Where
- 14 sites in United States, Czechia and 1 more
- Volunteers
- 43 people
- Sponsor
- Taiho Oncology, Inc.
Healthy Pregnant Women
Milk Free From A1-Type β-Casein on Inflammation, Gastrointestinal Tolerance, and Pregnancy Outcomes
The aim of the study is to compare the effects of conventional Ultra High Temperature (UHT) milk containing both A1 and A2 type β-caseins (CON) with a2 UHT Milk containing A2 type β-casein only (A1PF) on inflammation, tolerance…
- Trial name
- NCT06980376
- Testing
- a2 UHT milk, Conventional UHT Milk
- Where
- 6 sites in China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- a2 Milk Company Ltd.
Infertility, Female
Randomized Trial Comparing Early "Trigger" Versus Delayed "Trigger" Timing in Cycles of Controlled Ovarian Stimulation.
This randomized trial will compare the efficacy of two different times of administration of medications for final oocyte maturation, commonly called a "trigger", in cycles of controlled ovarian stimulation (COS) for cycles in…
- Trial name
- NCT05498350
- Testing
- Ovulatory trigger timing
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Fertility Center of Las Vegas
Cervical Cancer
Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
This study was to evaluate the safety and tolerability of bintrafusp alfa in combination with other anti-cancer therapies in participants with locally advanced or advanced cervical cancer.
- Trial name
- NCT04551950
- Testing
- M7824, Carboplatin, Paclitaxel
- Where
- 13 sites in United States, Japan and 1 more
- Volunteers
- 25 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Renal Cell Carcinoma, Kidney Cancer
Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma
This study evaluates the use of NanoDoce injected directly into tumors in the kidney of people with renal cell carcinoma.
- Conditions
- Renal Cell Carcinoma, Kidney Cancer, Adenocarcinoma of Kidney, Adenocarcinoma, Renal
- Trial name
- NCT04260360
- Testing
- NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension
- Sponsor
- NanOlogy, LLC
Infertility
Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine Contractions
This trial investigates the effects of FE 200440 compared to placebo on implantation rate in women undergoing IVF/ICSI treatment
- Trial name
- BASIC (NCT01723982)
- Testing
- Barusiban (FE 200440)
- Where
- 14 sites in Australia, Belgium and 4 more
- Volunteers
- 256 people
- Sponsor
- Ferring Pharmaceuticals
Metastatic Colorectal Cancer, Metastatic Cervical Cancer
Safety of Effivia®, a Bevacizumab Biosimilar
This is a post-marketing observational study aimed to evaluated the safety profile of Effivia®, a biosimilar of bevacizumab, in mexican patients with different types of cancer.
- Conditions
- Metastatic Colorectal Cancer, Metastatic Cervical Cancer, Non Squamous Non Small Cell Lung Cancer
- Trial name
- NCT06313268
- Testing
- Bevacizumab Biosimilar MB02
- Where
- 5 sites in Mexico
- Volunteers
- 83 people
- Sponsor
- Laboratorios Liomont
Preterm Labor, Preterm Birth
Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs
This prospective, randomized, controlled study evaluates the safety and efficacy of a preterm birth (PTB) prevention strategy versus standard of care pregnancy management to reduce the incidence of adverse pregnancy outcomes.
- Trial name
- PRIME (NCT04301518)
- Testing
- Multimodal intervention strategy
- Where
- 18 sites in United States
- Volunteers
- 6,500 people, healthy volunteers welcome
- Sponsor
- Sera Prognostics, Inc.
Hepatitis
Twinrix Pregnancy Registry
The purpose of the Twinrix Pregnancy Registry is to prospectively collect data describing exposure to Twinrix before or during pregnancy, potential confounding factors (such as exposure to other medications) and information…
- Trial name
- NCT03619590
- Testing
- Data Collection
- Volunteers
- 245 people
- Sponsor
- GlaxoSmithKline
Urothelial Carcinoma
A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
The purpose of this study is to determine the appropriate dose of AEZS-108 to treat patients with a tumor of the urinary system.
- Trial name
- NCT01234519
- Testing
- AEZS-108, AEZS-108 at MTD
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- AEterna Zentaris
Menorrhagia
Mirena or Conventional Medical Treatment for Menorrhagia
The aim of this prospective, non-interventional post-marketing surveillance study is to obtain data on safety and efficacy of Mirena in treatment of prolonged or heavy menstrual bleeding (Menorrhagia) under daily-life treatment…
- Trial name
- NCT00864136
- Testing
- Levonorgestrel (Mirena, BAY86-5028), Conventional medical treatment
- Where
- 8 sites in China, Hong Kong and 6 more
- Volunteers
- 647 people
- Sponsor
- Bayer
Infertility, Female
Study on the Pharmacokinetics and Safety of QL1012D and Gonal-F® in Healthy Female Volunteers
The goal of this Interventional study is to Compare the Pharmacokinetics and Safety of Recombinant Human Follicle Stimulating Hormone Injection (QL1012D) and Gonal-F® in Healthy Female Volunteers.
- Trial name
- NCT06864793
- Testing
- QL1012D, Gonal-F®
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
HPV Infections, Cervical Cancer
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
The study will evaluate the immunogenicity and safety of 9-valent HPV recombinant vaccine in Chinese healthy females16 to 26 years of age.
- Conditions
- HPV Infections, Cervical Cancer, Vulvar Cancer, Vaginal Cancer
- Trial name
- NCT05372016
- Testing
- Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58), Active Comparator: GARDASIL ®9
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Endometrial Cancer, Endometrial Cancer Recurrent
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Study RGX-104-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-104, an oral small molecule targeting the liver X receptor (LXR), as a single agent and in combination with nivolumab, ipilimumab…
- Conditions
- Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer
- Trial name
- NCT02922764
- Testing
- RGX-104, Ipilimumab, Docetaxel
- Where
- 21 sites in United States
- Volunteers
- 146 people
- Sponsor
- Inspirna, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.